71
Participants
Start Date
February 19, 2024
Primary Completion Date
September 5, 2025
Study Completion Date
March 6, 2026
vepdegestrant
Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
PF-07220060
Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
Institut Jules Bordet, Anderlecht
Antwerp University Hospital, Edegem
UZ Leuven, Leuven
AZ Groeninge Campus Kennedylaan, Kortrijk
Rockefeller Outpatient Pavilion (53rd Street), New York
Evelyn H. Lauder Breast and Imaging Center (BAIC)., New York
Memorial Sloan Kettering Cancer Center, New York
MSK Westchester, Harrison
MSK Nassau, Uniondale
MSK Commack, Commack
Institut Paoli-Calmettes, Marseille
Hospital Universitario Arnau de Vilanova de Lleida, Lleida
Hospital Universitario 12 de Octubre, Madrid
Institut Régional du Cancer Montpellier, Montpellier
Hospital Universitario Virgen Del Rocio, Seville
Institut de Cancérologie de l'Ouest, Saint-Herblain
START Midwest, Grand Rapids
Highlands Oncology, Fayetteville
Highlands Oncology, Rogers
Highlands Oncology Group, Springdale
START San Antonio, San Antonio
UCHealth Poudre Valley Hospital, Fort Collins
UCHealth Harmony, Fort Collins
UCHealth - Medical Center of the Rockies, Loveland
UCHealth Greeley Hospital, Greeley
Huntsman Cancer Institute, Salt Lake City
START Mountain Region, West Valley City
Hoag Health Center Irvine, Irvine
Hoag Hospital Irvine, Irvine
Hoag Memorial Hospital Presbyterian, Newport Beach
UCSF Medical Center at Mission Bay, San Francisco
Stanford Cancer Center, Palo Alto
Stanford Cancer Institute - Clinical Trials Office, Palo Alto
Wuhan Union Hospital Cancer Center, Wuhan
Sun Yat-sen University Cancer Center, Guangzhou
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Kanagawa cancer center, Yokohama
Smilow Cancer Hospital - Yale New Haven Health, New Haven
Yale - New Haven Hospital - Yale Cancer Center, New Haven
Smilow Cancer Hospital Phase 1 Unit, New Haven
Smilow Cancer Hospital - Trumbull, Trumbull
MSK Basking Ridge, Basking Ridge
MSK Monmouth, Middletown
MSK Bergen, Montvale
The Ottawa Hospital - General Campus, Ottawa
Sunnybrook Research Institute, Toronto
Princess Margaret Cancer Centre, Toronto
National Cancer Center Hospital East, Kashiwa
National Cancer Center Hospital, Chuo-ku
Showa Medical University Hospital, Tokyo
BRCR Global - Mayaguez Administrative Office, Mayagüez
BRCR Global - Mayagüez, Mayagüez
Pan American Center for Oncology Trials, LLC, Rio Piedras
Hospital Universitari Vall d'Hebron, Barcelona
Lead Sponsor
Arvinas Estrogen Receptor, Inc.
INDUSTRY
Pfizer
INDUSTRY